Aura Biosciences Inc
AURA
NASDAQ
Biotechnology
$7.69
USD
+0.04 (+0.52%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $793.34M
Volume 684.5K
Revenue
$0
TTM
— YoY
Gross Margin
—
TTM
— YoY
Net Income
$-131.01M
TTM
-29.2%
YoY
Operating Cash Flow
$-103.01M
TTM
-23.6%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.7 | 5.7 | 5.3 | 6.9 | 17.3 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 28.6 | 27.9 | 27.2 | 34.9 | 48.1 |
Operating Income | -28.6 | -27.9 | -27.2 | -34.9 | -48.1 |
EBITDA | -28.3 | -27.6 | -27.0 | -34.6 | -47.8 |
Other Income / Expense | -0.0 | -0.0 | 0.1 | 0.0 | 0.2 |
Total Other Income / Expense | 1.6 | 1.8 | 1.7 | 1.2 | 2.5 |
Income Before Income Taxes | -27.0 | -26.1 | -25.5 | -33.7 | -45.6 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -27.0 | -26.1 | -25.6 | -33.7 | -45.6 |
Consolidated Net Income / Loss | -27.0 | -26.1 | -25.6 | -33.7 | -45.6 |
Net Income Attributable to Common Shareholders | -27.0 | -26.1 | -25.6 | -33.7 | -45.6 |
Basic EPS | -$0.47 | -$0.40 | -$0.38 | -$0.50 | -$0.48 |
Diluted EPS | -$0.47 | -$0.40 | -$0.38 | -$0.50 | -$0.48 |
Basic Shares Outstanding | 58.0M | 65.9M | 67.3M | 67.4M | 94.9M |
Diluted Shares Outstanding | 58.0M | 65.9M | 67.3M | 67.4M | 94.9M |